In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer ...